Hubbry Logo
PhospholipasePhospholipaseMain
Open search
Phospholipase
Community hub
Phospholipase
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Phospholipase
Phospholipase
Phospholipase
View on Wikipedia
from Wikipedia
Phospholipase cleavage sites. An enzyme that displays both PLA1 and PLA2 activities is called a phospholipase B.

A phospholipase is an enzyme that hydrolyzes phospholipids[1] into fatty acids and other lipophilic substances. There are four major classes, termed A, B, C, and D, which are distinguished by the type of reaction which they catalyze:

Types C and D are considered phosphodiesterases.

Endothelial lipase is primarily a phospholipase.[2]

Phospholipase A2 acts on the intact lecithin molecule and hydrolyzes the fatty acid esterified to the second carbon atom. The resulting products are lysolecithin and a fatty acid. Phospholipase A2 is an enzyme present in the venom of bees, blennies and viper snakes.[3]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Phospholipase

View on Grokipedia
from Grokipedia
Phospholipases are a class of enzymes that catalyze the of phospholipids at specific linkages, generating a variety of molecules and playing essential roles in cellular processes such as membrane remodeling, , and . They are classified into four main types—A, B, C, and D—based on the position of the bond they cleave: phospholipase A1 (PLA1) hydrolyzes the at the sn-1 position, (PLA2) at the sn-2 position to release free fatty acids like , phospholipase B (PLB) acts on both sn-1 and sn-2 positions, (PLC) cleaves the glycerophosphate bond to produce diacylglycerol and a phosphate-containing head group, and (PLD) removes the polar head group to yield . This classification encompasses numerous subfamilies and isoforms, with over 30 distinct PLA2 enzymes alone, reflecting their evolutionary diversity and functional specialization across organisms from to humans. In biological systems, phospholipases are ubiquitous and tightly regulated, often activated by cellular signals such as calcium ions or hormones, and they contribute to critical pathways including , where PLA2 generates precursors for eicosanoids like prostaglandins, and , where PLC produces second messengers. Dysregulation of these enzymes is implicated in various diseases, including , cancer, and neurodegenerative disorders, making them targets for therapeutic intervention, though no phospholipase inhibitors are currently approved for clinical use. Beyond , phospholipases have industrial applications in for degumming oils and in for modifying , underscoring their broad significance.

Overview

Definition and General Properties

Phospholipases constitute a diverse class of lipolytic enzymes that catalyze the of , which are the primary structural components of cell membranes in living organisms. These enzymes are grouped together based on their shared ability to cleave bonds within phospholipid substrates, though they vary widely in , specificity, and biological roles. Phospholipases are classified under Enzyme Commission (EC) numbers in subclasses 3.1.1 (carboxylic hydrolases, such as types A and B) and 3.1.4 (phosphoric diester hydrolases, such as types C and D), reflecting their distinct catalytic mechanisms on or diester linkages. They are ubiquitous across kingdoms of life, from to mammals, and play essential roles in by breaking down these amphipathic molecules at interfaces like micelles or bilayers. The general catalytic reaction involves the nucleophilic attack on specific bonds in , resulting in the release of products such as lysophospholipids, free s, diacylglycerol, or , depending on the site of . substrates typically feature a glycerol backbone with chains esterified at the sn-1 and sn-2 positions, a phosphate moiety attached at the sn-3 position, and a polar head group—such as choline in the common substrate or ethanolamine in . This stereospecific numbering (sn) denotes the chiral configuration, with substrate specificity often targeting the sn-1 acyl chain, sn-2 acyl chain, or the phosphodiester linkage to the head group, though without strict exclusivity across the class. Key physicochemical properties of phospholipases include their frequent dependence on calcium ions (Ca²⁺) for activity, where millimolar concentrations for secretory forms or micromolar levels for cytosolic variants promote interfacial binding or stabilize catalytic residues. These enzymes exhibit interfacial activation, becoming more efficient when s aggregate above their critical micellar concentration, and can be either water-soluble proteins that transiently associate with membranes or integral membrane-associated forms. Optimal activity generally occurs at neutral to slightly alkaline values, typically ranging from 7 to 9, aligning with physiological conditions in eukaryotic cells. This diversity in properties underscores their adaptability to various cellular environments while maintaining the core function of degradation.

Historical Background

The enzymatic activity now known as phospholipase A was first identified in the early through studies on snake venoms and pancreatic extracts. In 1911–1912, Charles Delezenne and Simon Ledebt demonstrated that snake venoms, particularly from viper species, contained an —initially termed lecithinase—that hydrolyzed into hemolytic lysolecithin, explaining the venom's lytic effects on red cells. Similar phospholipase A activity was observed in pancreatic tissues shortly thereafter, with Angelo Contardi and Alberto Ercoli describing in 1933 the selective of the sn-2 acyl chain in lecithins by pancreatic preparations, distinguishing it from other lipases. These discoveries laid the foundation for recognizing phospholipases as key players in degradation, initially under descriptive names like "lecithinase A." In the and , research expanded to other phospholipase types, particularly from bacterial sources. was isolated from (formerly known as C. welchii) as its alpha-toxin in 1941 by Macfarlane and Knight, who showed it hydrolyzed phospholipids into phosphorylcholine and diacylglycerol, contributing to the bacterium's pathogenicity in . This isolation marked a milestone in understanding bacterial toxins. Naming conventions evolved during this period, with "phospholipase" gaining prominence over "lecithinase" to reflect broader substrate specificity. By the mid-1950s, the International Union of Pure and Applied Chemistry (IUPAC) and the International Union of Biochemistry began standardizing enzyme nomenclature, culminating in the 1961 Enzyme Commission (EC) system, which assigned EC 3.1.1.4 to and EC 3.1.4.3 to . The 1960s brought key advancements in purification, characterization, and mechanistic insights across phospholipase types. R.M.C. Dawson's work in lipid biochemistry during this decade was instrumental, including his 1963 elucidation of phospholipase A's interfacial activation on lipid-water interfaces and the role of calcium in catalysis, using model substrates like lecithin monolayers. Phospholipase A2 from cobra venom (Naja naja) was purified to homogeneity in the late 1960s, enabling early structural analyses that revealed conserved disulfide bonds and active site residues. By the early 1970s, the recognition of phospholipase A2's role in releasing arachidonic acid from membrane phospholipids—pioneered by studies on mammalian cells—highlighted its involvement in eicosanoid biosynthesis, shifting focus from toxicity to physiological regulation. This period also saw the transition from empirical names like "lecithinase" to the systematic EC classification, facilitating comparative biochemistry across organisms.

Classification

Phospholipase A Family

The phospholipase A family encompasses enzymes that catalyze the hydrolysis of the acyl ester bond at either the sn-1 or sn-2 position of glycerophospholipids, generating lysophospholipids and free fatty acids as products. These enzymes play key roles in lipid metabolism and are classified primarily into phospholipase A1 (PLA1) and phospholipase A2 (PLA2) based on the specific position of cleavage. Phospholipase A1 (PLA1) specifically hydrolyzes the fatty acid at the sn-1 position of phospholipids, yielding 2-acyl-lysophospholipids and a free . PLA1 enzymes are less commonly studied compared to their PLA2 counterparts and are notably present in lysosomal compartments, where they contribute to intracellular degradation. In contrast, (PLA2) hydrolyzes the acyl chain at the sn-2 position, releasing free fatty acids—often , a precursor to bioactive eicosanoids—and lysophospholipids such as . Mammals express over 15 isoforms of PLA2, including secretory forms (sPLA2) that are extracellular and calcium-dependent, and cytosolic forms (cPLA2) that are intracellular and preferentially release . PLA2 enzymes are further subclassified into groups I through VI (and beyond in the broader superfamily) based on sequence homology, the presence of bonds, calcium dependence, and cellular localization. For instance, Group IIA sPLA2 is prominently involved in inflammatory responses due to its high expression in immune cells and potent activity on aggregated phospholipids. Representative examples include pancreatic PLA2 (Group IB), a secreted that aids in dietary digestion by hydrolyzing phospholipids in the intestinal lumen. Bee venom PLA2 serves as a well-characterized model for structural and functional studies of the family, owing to its stability and ease of purification. The catalytic activity of PLA2 follows Michaelis-Menten kinetics, with typical Km values for substrates ranging from approximately 10 to 100 μM under assay conditions that mimic physiological interfaces. Phospholipase B (PLB), also known as lysophospholipase, exhibits both PLA1 and PLA2 activities, sequentially hydrolyzing the acyl groups at the sn-1 and sn-2 positions of glycerophospholipids to produce free fatty acids and glycerophosphocholine. These enzymes contribute to lipid degradation and are found in various organisms, including fungi and mammals.

Phospholipase C and D Families

(PLC) enzymes catalyze the of phospholipids at the bond distal to the group, resulting in the production of diacylglycerol (DAG) and a phosphorylated head group. A key example is the cleavage of (PIP2), which yields DAG and 1,4,5-trisphosphate (IP3): PIP2→DAG+IP3\text{PIP}_2 \rightarrow \text{DAG} + \text{IP}_3 This reaction is central to phosphoinositide signaling in eukaryotic cells. Mammalian PLCs are classified into several isoforms, including β, γ, δ, ε, and ζ, each with distinct regulatory mechanisms and tissue distributions. For instance, PLCβ isoforms are primarily activated by G-protein-coupled receptors, while PLCγ responds to receptor kinases. PLC enzymes are predominantly localized to the plasma membrane, where they interact with their lipid substrates. Bacterial PLCs, such as the α-toxin produced by , exhibit similar hydrolytic activity but serve as virulence factors in infections like . This toxin hydrolyzes and in host cell membranes, leading to membrane disruption and cell lysis, thereby enhancing bacterial pathogenicity. (PLD) enzymes, in contrast, hydrolyze the between the phosphate and the head group of phospholipids, producing (PA) and the free head group. The primary substrate in mammals is (PC), which is converted to PA and choline: PC→PA+choline\text{PC} \rightarrow \text{PA} + \text{choline} This process is dependent on PIP2 as a cofactor, with activity often regulated by Ca2+ in certain cellular contexts. Mammals express two main isoforms, PLD1 and PLD2, which share structural homology but differ in subcellular distribution and regulation; PLD1 is often associated with vesicular trafficking, while PLD2 is more broadly distributed. PLD isoforms are primarily localized to endomembranes, including Golgi and endosomal compartments, facilitating their roles in intracellular dynamics.

Molecular Structure

Domains and Active Sites

Phospholipases exhibit diverse structural domains that facilitate substrate recognition, membrane association, and catalysis, with (PLA2) serving as a prototypical example due to its well-characterized atomic features. Secreted PLA2 enzymes, such as those from bovine , feature a compact α/β fold stabilized by multiple bonds, including a calcium-binding loop that coordinates a catalytically essential Ca²⁺ . In cytosolic PLA2 (cPLA2), an N-terminal C2 domain contains EF-hand-like calcium-binding loops that enable Ca²⁺-dependent targeting to membranes, promoting interfacial activation upon binding. This C2 domain adopts a β-sandwich structure with three Ca²⁺-binding loops, where aspartate and glutamate residues coordinate the ions to reorient basic residues like lysines for electrostatic interaction with anionic phospholipids. The of PLA2 is a deep pocket at the protein's core, featuring a catalytic dyad composed of (His48) and aspartate (Asp99) residues that facilitate nucleophilic attack on the sn-2 acyl bond. The conserved acts as a general base to deprotonate a molecule, enabling , while the aspartate stabilizes the imidazolium of . Ca²⁺ coordination involves residues such as Asp49, Tyr28, Gly30, and Gly32 in PLA2s, which position the cofactor to activate the hydrolytic and orient the substrate's ; this site is similarly conserved in mammalian secretory PLA2s. An interfacial binding surface, or i-face, comprising hydrophobic residues like Tyr and Phe on a concave region opposite the , allows insertion and aggregation of phospholipids for efficient . The first high-resolution crystal structure of bovine pancreatic PLA2, refined to 1.7 Å, revealed this conserved architecture, including the nucleophile and disulfide connectivity, establishing the structural basis for Ca²⁺ dependence across group I-III PLA2s. Structural variations exist among phospholipase families. In (PLC), a pleckstrin homology (PH) domain binds (PIP2) via basic residues like lysines and arginines in a positively charged , facilitating recruitment without Ca²⁺ involvement in substrate binding. Bacterial PLCs, such as those from , lack Ca²⁺ dependence and instead rely on a zinc-binding with two s and a glutamate coordinating Zn²⁺ for . (PLD) enzymes contain two conserved HKD motifs (His-Lys-Asp), which form a binuclear where the histidines act as nucleophiles in a two-step mechanism, as seen in the first 1.9 Å crystal structure of a sp. PLD. In some phospholipase A1 (PLA1) isoforms, such as pancreatic lipases with PLA1 activity, a serine residue serves as the in a (Ser-His-Asp), enabling sn-1 acyl hydrolysis without Ca²⁺ requirement, distinct from the histidine-based mechanism of PLA2.

Variations Across Organisms

In prokaryotes, phospholipases are often secreted enzymes lacking complex membrane-targeting domains, facilitating extracellular activity. For instance, PlcHR2 in is a zinc-independent that hydrolyzes and , contributing to bacterial virulence without intracellular regulatory motifs typical of eukaryotic counterparts. In eukaryotic animals, phospholipases exhibit more intricate multidomain architectures adapted for regulated intracellular localization. Mammalian cytosolic (cPLA2α), an 85 kDa protein, features an N-terminal C2 domain that binds calcium ions, enabling Ca²⁺-triggered translocation from the to cellular membranes for targeted . This domain-mediated mechanism contrasts with simpler prokaryotic forms, allowing precise control in response to signaling cues. Plant phospholipases display unique adaptations suited to developmental and stress responses, often resembling nonspecific acyl hydrolases. Patatins from potato (Solanum tuberosum) tubers represent a prominent example, functioning as vacuolar lipid acyl hydrolases that cleave acyl chains from glycerolipids without strict specificity for phospholipid head groups. In Arabidopsis thaliana, NPC3 serves as a phosphatidylcholine-hydrolyzing phospholipase C involved in phospholipid turnover during phosphate limitation, localized primarily to vegetative tissues like roots and leaves. Fungal and other microbial phospholipases often combine multiple catalytic activities within single enzymes, enhancing versatility in host interactions. In , phospholipase B (Plb) exhibits dual phospholipase A and lysophospholipase activities, enabling sequential deacylation of phospholipids to support fungal growth and pathogenesis. Viral phospholipases further illustrate microbial diversity; for example, hepatitis C virus modulates host membranes through indirect phospholipase activation, promoting replication formation via lipid remodeling. Evolutionarily, the phospholipase A2 (PLA2) family has expanded through gene duplications, resulting in over 30 PLA2-related genes in humans compared to fewer in simpler organisms like or basal eukaryotes. This proliferation, evident in mammalian genomes with multiple clusters (e.g., six genes in the group II PLA2 locus), has driven functional diversification while retaining core catalytic motifs.

Catalytic Mechanisms

Hydrolysis Reactions

Phospholipases catalyze the of phospholipids through a nucleophilic attack by a on the carbonyl carbon (for PLA family) or phosphorus atom (for PLC and PLD families), forming a tetrahedral intermediate that collapses to yield free fatty acids, lysophospholipids, diacylglycerol, or , depending on the class. In some cases, such as certain serine-dependent phospholipases, an acyl- intermediate forms transiently, but this is not observed in the Ca²⁺-dependent secretory PLA2, where direct proceeds without covalent enzyme-substrate linkage. The general process involves of as the , often facilitated by residues, with the tetrahedral intermediate stabilized by metal ions or hydrogen bonding networks to lower the barrier, typically around 15-20 kcal/mol for PLA2-mediated reactions. The (PLA2) family exemplifies the mechanism in detail, particularly the secreted isoforms, which cleave the sn-2 bond stereospecifically. The reaction proceeds in two steps: first, a molecule, deprotonated by His48 acting as a general base, performs a nucleophilic attack on the sn-2 carbonyl carbon, generating a tetrahedral intermediate whose is stabilized by coordination to Ca²⁺ as an equatorial , with additional support from the Gly30 backbone . Asp99 orients and stabilizes the imidazolium of His48 through hydrogen bonding, functioning as a proton shuttle to facilitate and subsequent protonation of the leaving alkoxide group during intermediate collapse. The simplified reaction for PLA2 is: R1−C(O)O−CH2−CH(O−C(O)−R2)−CH2−OPO3−X→R1−C(O)O−CH2−CH(OH)−CH2−OPO3−X+R2C(O)OH\mathrm{R_1-C(O)O-CH_2-CH(O-C(O)-R_2)-CH_2-OPO_3-X \rightarrow R_1-C(O)O-CH_2-CH(OH)-CH_2-OPO_3-X + R_2C(O)OH} where R₁ and R₂ are acyl chains, and X is the polar head group, yielding a lysophospholipid and free fatty acid; the energy barrier for this process is approximately 16.9 kcal/mol. Stereospecificity for the sn-2 position arises from Ca²⁺ binding to the sn-3 phosphate, enforcing chiral recognition of the L-glycerophospholipid substrate and excluding sn-1 hydrolysis. In contrast, phospholipase C (PLC) enzymes hydrolyze the phosphodiester bond via an inline SN2 nucleophilic attack on the phosphorus atom by an activated water molecule, often assisted by a general base such as histidine in the active site, leading to direct production of diacylglycerol and inositol phosphates. Some isoforms, particularly bacterial phosphatidylinositol-specific PLC, produce a cyclic inositol phosphate intermediate that is subsequently hydrolyzed, reflecting variations in the catalytic pathway. Phospholipase D (PLD) primarily hydrolyzes the terminal of to generate and choline but can also catalyze a competing transphosphatidylation reaction in the presence of primary alcohols, transferring the phosphatidyl group to form phosphatidyl alcohols instead of performing full . This side reaction proceeds through a similar nucleophilic mechanism but utilizes the alcohol as the acceptor , highlighting PLD's dual hydrolase-transferase capability.

Regulation of Activity

The activity of phospholipases is tightly regulated by various post-translational mechanisms to ensure precise control over lipid in cellular processes. A primary mode of regulation involves calcium ions (Ca²⁺), which play distinct roles across phospholipase families. For secretory phospholipase A2 (sPLA2) isoforms, micromolar concentrations of Ca²⁺ are essential for substrate binding and catalysis, facilitating extracellular . In contrast, cytosolic phospholipase A2 (cPLA2) requires micromolar Ca²⁺ levels (typically 1–10 μM) for translocation from the to cellular membranes via its C2 domain, with submicromolar to low micromolar Ca²⁺ sufficient for subsequent enzymatic activity once membrane-associated. This calcium-dependent translocation positions cPLA2 at sites rich in arachidonyl-containing , enabling targeted release of during inflammatory responses. Phosphorylation serves as another critical regulatory layer, often integrating phospholipase activity with upstream signaling cascades. In cPLA2, at serine residues by mitogen-activated protein kinases (MAPK), such as ERK and p38, enhances catalytic activity and promotes release, particularly in inflammatory contexts like cytokine-stimulated cells. For β (PLCβ) isoforms, (PKC) phosphorylates specific serine sites, such as Ser1105 in PLCβ3, leading to inhibition of G-protein-stimulated activity and thus dampening phosphoinositide . These events allow dynamic modulation, with MAPK/ERK pathways activating cPLA2 in response to growth factors or stress signals, while PKC provides on PLCβ to prevent overactivation. Endogenous inhibitors further fine-tune phospholipase function, preventing unchecked lipid mediator production. Annexins, particularly (formerly lipocortin-1), act as potent inhibitors of PLA2 by directly binding and suppressing enzymatic activity, thereby reducing liberation during . Substrate competition also contributes, where lysophospholipids or free fatty acids generated by phospholipase action can occupy active sites, limiting further . adds another dimension; for instance, (PIP2) binds allosterically to (PLD), enhancing its activity toward , while G-protein subunits (e.g., Gαq and Gβγ) allosterically activate PLCβ at distinct sites to couple receptor signals to generation. Feedback loops provide intrinsic control to maintain . Phosphatidic acid (PA), produced by PLD, inhibits PLCβ1 activity and its stimulation by G-proteins, creating a circuit that coordinates phosphoinositide and signaling. Similarly, , a product of PLA2 , exerts auto-regulatory effects by inhibiting further PLA2 activity through product inhibition or modulation of upstream kinases, thus preventing excessive production in inflammatory settings. These mechanisms ensure that phospholipase activity is responsive yet restrained, integrating with broader cellular lipid dynamics.

Biological Functions

Role in Membrane Dynamics

Phospholipases play a crucial role in dynamics by hydrolyzing phospholipids to generate products that alter , maintain lipid asymmetry, and facilitate vesicle trafficking. These enzymes enable rapid remodeling of lipid bilayers in response to cellular needs, influencing processes such as , , and fusion. For instance, (PLA2) produces lysophospholipids, which promote positive essential for vesicle budding, while (PLD) generates (PA), which induces negative to support invagination and fusion events. In membrane curvature regulation, PLA2-generated lysophospholipids, such as , accumulate in the inner leaflet of the plasma membrane, favoring positive curvature that drives by facilitating membrane . Conversely, PA produced by PLD adopts a conical shape due to its small headgroup relative to its acyl chains, promoting negative curvature that aids in processes like vesicle scission and fusion. These products thus provide biophysical cues for dynamic membrane shaping without requiring extensive protein scaffolding. Phospholipases also contribute to lipid asymmetry maintenance, particularly in erythrocytes where calcium-independent PLA2 (iPLA2) deacylates inner-leaflet phospholipids like (PS), preventing their exposure on the outer leaflet and preserving the transbilayer gradient essential for cell integrity. This remodeling activity ensures that anionic lipids remain sequestered, avoiding premature signaling for clearance. In vesicle formation, (PLC) generates diacylglycerol in the Golgi apparatus, supporting COPI vesicle budding by enhancing membrane deformability, while PLD-derived PA facilitates phagocytic cup formation during particle engulfment by macrophages. Turnover rates underscore the dynamic nature of these processes, with phospholipase-mediated occurring rapidly—often within seconds—upon cellular stimulation to generate curvature-altering , whereas the overall of membrane phospholipids typically spans hours under basal conditions, allowing sustained bilayer homeostasis. Representative examples include lysosomal PLA2 in alveolar macrophages, which degrades phospholipids to recycle dipalmitoylphosphatidylcholine, and PLD in , where PA production supports homotypic vacuole fusion by stabilizing SNARE-mediated docking. These mechanisms highlight phospholipases' biophysical contributions to membrane adaptability across eukaryotic systems.

Involvement in Signaling Pathways

Phospholipases play pivotal roles in cellular signaling by generating lipid second messengers that propagate signals from cell surface receptors to intracellular effectors. (PLC) is activated downstream of G protein-coupled receptors (GPCRs) or receptor tyrosine kinases (RTKs), leading to the hydrolysis of (PIP₂) into inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ diffuses to the , where it binds to IP₃ receptors to trigger calcium (Ca²⁺) release into the , while DAG remains membrane-bound and recruits (PKC) for activation, thereby amplifying downstream signaling cascades such as MAPK pathways. Phospholipase A₂ (PLA₂), particularly the cytosolic isoform cPLA₂α, contributes to eicosanoid-mediated signaling by liberating (AA) from membrane phospholipids upon stimulation. This AA serves as a substrate for (COX) and (LOX) enzymes, which convert it into bioactive eicosanoids including prostaglandins and leukotrienes that modulate and vascular tone. For instance, COX-derived prostaglandins like PGE₂ bind to specific receptors to influence production and . Phospholipase D (PLD) generates phosphatidic acid (PA), a key activator in the mammalian target of rapamycin (mTOR) pathway, by hydrolyzing phosphatidylcholine in response to growth factors or mechanical stimuli. PA directly binds to the FRB domain of mTOR, promoting mTOR complex 1 (mTORC1) assembly and activation to regulate protein synthesis and cell growth. Additionally, PLD can undergo transphosphatidylation in the presence of primary alcohols like ethanol, producing phosphatidylalcohols instead of PA and thereby attenuating mTOR signaling. Signaling pathways exhibit , such as the of cPLA₂α by Ca²⁺ mobilized via the PLC-IP₃ pathway, which links GPCR to AA release and production. , generated from hydrolysis, provides negative feedback by inhibiting PLD activity, thereby limiting PA accumulation and sustaining pathway balance. These are often transient, peaking within minutes of exposure; for example, induces PLC-mediated DAG production that maximizes at approximately 2 minutes before declining, allowing precise temporal control of Ca²⁺ signaling and downstream responses.

Physiological Roles

In Animals and Humans

In animals and humans, phospholipases play essential roles in various physiological processes, particularly in digestion, reproduction, neural function, immune responses, and metabolic homeostasis. These enzymes facilitate the hydrolysis of phospholipids to support lipid metabolism and cellular signaling in metazoan systems. Pancreatic secreted phospholipase A2 (sPLA2) is crucial for the digestion of dietary phospholipids in the small intestine, where it hydrolyzes the sn-2 acyl ester bond of phospholipids to release free fatty acids and lysophospholipids, aiding in the emulsification and absorption of fats. This activity is enhanced by bile salts, which activate sPLA2 by removing inhibitory phospholipids from the enzyme's surface, thereby promoting efficient lipid breakdown during meal processing. In reproduction, (PLA2) contributes to the in mammalian , an exocytotic event triggered by zona pellucida binding that releases hydrolytic enzymes necessary for penetration and fertilization. PLA2 activation leads to release, which supports membrane fusion and ion fluxes required for and acrosomal . Additionally, (PLD) regulates maturation by generating , a second messenger that modulates Src activity, calcium release, and cytoskeletal dynamics essential for meiotic resumption and progression to II. In neural processes, cytosolic (cPLA2) is involved in , where its activation releases to facilitate and formation in the . cPLA2-mediated signaling supports retrograde endocannabinoid production, which is critical for cerebellar synaptic depression and . Furthermore, PLA2 participates in myelin sheath turnover by hydrolyzing phospholipids in , influencing integrity and lipid remodeling during neuronal development and maintenance. This enzymatic activity helps regulate the polyunsaturated composition of , ensuring proper insulation and signal conduction. During immune responses, group IIA secreted (sPLA2-IIA) functions as an , upregulated in the liver and released into circulation in response to inflammatory cytokines like interleukin-6, contributing to host defense by degrading bacterial membranes and modulating lipid mediators. Its expression peaks during , enhancing activity without directly causing tissue damage in normal . In metabolic , (PLD), particularly the PLD1 isoform, regulates insulin secretion from pancreatic beta cells by hydrolyzing to produce , which promotes granule in response to glucose and other secretagogues. PLA2 enzymes, including cPLA2, serve as a of arachidonic acid release from membrane phospholipids, supporting production that fine-tunes beta-cell function and glucose .

In Plants and Microorganisms

In plants, phosphoinositide-specific (PI-PLC) enzymes play a key role in signaling by hydrolyzing (PIP2) to generate inositol 1,4,5-trisphosphate (IP3), which mobilizes intracellular calcium stores to initiate stress responses such as stomatal closure and changes. This pathway enhances , as demonstrated in where PLC3 overexpression improves water retention without altering root architecture. Patatin-like phospholipase A (PLA) enzymes contribute to the wounding response by hydrolyzing glycerolipids to release free fatty acids and lysolipids, which serve as precursors for oxylipin signaling and promote jasmonate-mediated defense activation at injury sites. For instance, activation of PLA2 activity in communis leaves following mechanical damage leads to rapid lipid breakdown, facilitating localized repair and pathogen deterrence. Additionally, (PLD) is essential for production during wounding, as it generates that supplies for subsequent conversion into jasmonates, with antisense suppression of PLDα reducing levels by up to 50% in . In microorganisms, bacterial PLC acts as a , particularly in , where it facilitates host cell invasion by hydrolyzing phospholipids in the vacuolar to enable bacterial escape and intracellular spread. The broad-range PLC (plcB) and phosphatidylinositol-specific PLC (plcA) exhibit overlapping functions, with mutants showing impaired cell-to-cell dissemination in murine models. Fungal phospholipase B (PLB) supports hyphal extension by remodeling lipids to maintain fluidity and vesicle trafficking at growing tips, as seen in opportunistic pathogens like where PLB activity correlates with polarized growth and tissue invasion. In , the PLD homolog Spo14p is indispensable for sporulation and , relocalizing to prospore to generate that drives membrane proliferation and nuclear packaging during ascospore formation. Spo14p mutants arrest in I, underscoring its role in coordinating synthesis with meiotic progression. Phospholipases also aid environmental adaptation in microorganisms; in , phospholipase B (PaPlaB) influences formation by hydrolyzing endogenous phospholipids, altering matrix architecture and reducing aggregation to enhance surface colonization under nutrient-limited conditions. Similarly, phospholipases mediate remodeling under nutrient stress, such as , where bacterial intracellular PLC (e.g., PlcP in marine ) catabolizes phospholipids to substitute with non-phosphorus , preserving and enabling survival in oligotrophic environments. In stressed , PLA-driven turnover can account for substantial remodeling of to adjust and signaling efficiency during stresses such as . These adaptations highlight phospholipases' conserved yet specialized roles in sessile and unicellular organisms, distinct from multicellular animal processes by emphasizing stress resilience and .

Clinical and Pathological Significance

Association with Diseases

Phospholipases play critical roles in various pathological conditions through dysregulation of and membrane remodeling. In inflammatory diseases, elevated levels of secretory phospholipase A2 group IIA (sPLA2-IIA) are prominently associated with , where increased enzyme activity in promotes degradation and joint inflammation by hydrolyzing phospholipids to release precursors for pro-inflammatory eicosanoids. Similarly, sPLA2-IIA levels rise markedly in , correlating with systemic inflammation, organ dysfunction, and higher mortality rates due to amplified storms and endothelial damage. Cytosolic phospholipase A2 (cPLA2) contributes to by activating release, which fuels biosynthesis, exacerbating airway hyperresponsiveness and inflammation. In cancer, phospholipase C gamma 1 (PLCγ1) overexpression drives aberrant signaling in , enhancing pathways that stimulate , survival, and metastatic potential, serving as a prognostic marker for poor outcomes. Phospholipase D1 (PLD1) facilitates tumor invasion across multiple malignancies, including , by upregulating matrix metalloproteinase-13 (MMP-13) expression via activation, thereby promoting degradation and cancer cell motility. Neurodegenerative disorders involve (PLA2) hyperactivity, particularly in , where activated cPLA2 localizes to amyloid-beta plaques, triggering , , and synaptic loss that accelerate cognitive decline. Mutations in the PLA2G6 gene, encoding calcium-independent PLA2 group VI, underlie infantile neuroaxonal dystrophy, leading to dystrophic axons, cerebellar atrophy, and progressive motor deficits. Cardiovascular pathologies link phospholipases to plaque vulnerability and myocardial impairment. sPLA2-IIA exacerbates by infiltrating plaques, hydrolyzing lipoproteins to generate and free fatty acids, which foster formation and plaque instability prone to rupture. In diabetic , (PLD) activity is diminished in cardiac membranes, disrupting phosphatidic acid-mediated signaling essential for contractility and calcium handling, thereby contributing to systolic dysfunction and . Genetic disorders highlight phospholipase deficiencies as direct causes of pathology. PLA2G6 mutations result in enzyme deficiency, causing aberrant phospholipid accumulation in brain membranes and mitochondria, which triggers oxidative stress, iron deposition, and neurodegeneration; these links were substantiated through genetic studies in the 2010s identifying biallelic variants in affected families.

Therapeutic Targeting and Inhibitors

Phospholipase A2 (PLA2) inhibitors have been developed to mitigate excessive inflammatory responses linked to various pathologies. Varespladib, a potent inhibitor of secretory PLA2 (sPLA2), indirectly blocks lipoxygenase (LOX) and cyclooxygenase (COX) pathways by preventing the release of arachidonic acid from phospholipids. It has shown mixed results but promise in a 2024 phase II clinical trial (BRAVO) for snakebite envenoming, with potential benefits in early treatment subgroups (within 5 hours) for reducing severity scores and good safety/tolerability (mild adverse events such as abdominal pain). Mepacrine (quinacrine), a non-specific PLA2 inhibitor, has been used in experimental settings to suppress PLA2-mediated lipolysis and fatty acid acylation, though its broad activity limits clinical utility due to off-target effects. For (PLC), U73122 serves as a widely adopted tool, potently inhibiting PLC activity and agonist-induced in cells like platelets and neutrophils, with values in the 1-5 μM range. In therapeutic contexts, edelfosine (ET-18-OCH3), an alkyl-lysophospholipid that selectively inhibits phosphatidylinositol-specific PLC at cytotoxic concentrations, has advanced to clinical trials for , including liposomal formulations that induce c-mediated in leukemic cells independently of CD95. Phase I/II trials of edelfosine in and other hematologic malignancies have reported improved pharmacokinetics and antitumor activity, though gastrointestinal toxicities were noted. Phospholipase D (PLD) inhibitors target isoforms implicated in cancer progression. Derivatives of halopemide, such as FIPI, block both PLD1 and PLD2, disrupting F-actin rearrangement and cell invasiveness in tumor models. VU0285655 (also known as BML-280), a selective PLD2 inhibitor, prevents caspase-3 cleavage and reduces proliferation in cancer cells, including astroglial lines, with efficacy at nanomolar concentrations. These compounds highlight PLD as a viable anticancer target, though isoform-selective variants are prioritized to minimize redundancy. Clinical development of phospholipase inhibitors includes the phase II FRANCIS trial (2010) for sPLA2 inhibition in , where varespladib demonstrated dose-dependent reductions in sPLA2-IIA levels; however, the subsequent phase III VISTA-16 trial (terminated 2013) failed to lower and showed increased risk of . Recent phase II trials as of 2025, such as varespladib for envenoming (completed 2024 with phase III planning) and SR1375 for (initiated 2024), have shown promising signals. Gene therapies, such as /Cas9-mediated knockdown, have been employed in preclinical models; for instance, knockout of PLCδ1 in mice revealed roles in and abnormalities, while PNPLA5 (a patatin-like PLA2) rats exhibited bleeding disorders and altered hematobiochemistry, informing therapeutic strategies for inflammatory diseases. As of 2025, emerging research highlights cPLA2 as a target for degenerative joint diseases; preclinical studies show that inhibitors, including repurposed over-the-counter drugs like fexofenadine, reduce degeneration and in and intervertebral disc degeneration models. Developing phospholipase inhibitors faces significant hurdles, including achieving isoform specificity amid functional redundancy, as multiple isoforms often compensate for inhibition of a single one, reducing efficacy in complex diseases like cancer and . Side effects, particularly gastrointestinal issues such as and nausea, are common with PLA2 inhibitors like varespladib and darapladib, complicating long-term use.

Research and Applications

Experimental Techniques

Experimental techniques for studying phospholipases encompass a range of biochemical, structural, genetic, and imaging methods designed to measure enzyme activity, elucidate molecular structures, manipulate , and visualize dynamic processes in cellular contexts. These approaches enable precise characterization of phospholipase isoforms, such as (PLA2), (PLC), and (PLD), and their roles in lipid hydrolysis. Activity assays are fundamental for quantifying phospholipase function, often relying on substrate detection. Fluorometric assays using nitrobenzoxadiazole (NBD)-labeled , such as NBD-lyso-PAF, allow sensitive measurement of PLA2 activity by monitoring fluorescence changes upon product formation, suitable for high-protein biological samples. Radioactive assays track [³H] release from pre-labeled phospholipids, providing a direct readout of PLA2-mediated sn-2 bond cleavage in cellular systems. (HPLC) separates and quantifies products like lysophospholipids and free fatty acids, often coupled with fluorescence or mass detection for isoform-specific analysis. These methods collectively assess catalytic efficiency under varying conditions, including calcium dependence for regulated isoforms. Structural methods reveal atomic-level details of phospholipase-lipid interactions. has resolved PLA2-lipid complexes, highlighting interfacial binding motifs and catalytic residues essential for substrate recognition. Cryo-electron microscopy (cryo-EM) captures membrane-bound PLC conformations, such as PLCε in complex with regulatory proteins, elucidating activation mechanisms at bilayers. Genetic tools facilitate isoform-specific functional studies. mice lacking cytosolic PLA2 (cPLA2, group IVA) exhibit reduced fertility due to impaired mobilization in reproductive tissues. (siRNA) knockdown targets individual isoforms, such as calcium-independent PLA2β, to dissect contributions to cellular signaling without global disruption. Imaging techniques provide spatiotemporal insights into phospholipase dynamics. Förster resonance energy transfer ()-based sensors monitor real-time PLC activity through calcium-induced IP3 production, linking to downstream Ca²⁺ signaling. Mass spectrometry-based profiles phospholipase-generated lipid species, enabling comprehensive mapping of products in tissues. Quantification of inhibitor potency uses half-maximal inhibitory concentration () values, typically in the nanomolar to micromolar range, as seen with selective cPLA2 inhibitors blocking release. These metrics guide development of tools probing phospholipase regulation, including Ca²⁺-dependent activation assays.

Industrial and Pharmaceutical Uses

Phospholipases play a significant role in the , particularly in oil processing. Lecitase® Ultra, a phospholipase A1 (PLA1) derived from , is widely used for enzymatic degumming of crude , where it hydrolyzes phospholipids to facilitate their removal and reduce content to levels below 10 ppm from initial concentrations often exceeding 700 ppm, achieving over 90% reduction without requiring a subsequent wash. This process improves oil yield, minimizes waste, and enhances the efficiency of physical refining compared to traditional acid degumming methods. In pharmaceutical applications, recombinant (PLA2) is employed in stimuli-responsive systems, such as liposomes designed to disrupt upon exposure to elevated PLA2 levels in pathological environments like tumors or inflamed tissues, enabling targeted release of encapsulated therapeutics. Similarly, (PLD) facilitates the enzymatic synthesis of head-group modified phospholipids, which serve as key ingredients in due to their emulsifying and moisturizing properties that enhance and hydration. These head-group modified phospholipids, produced via PLD-catalyzed transphosphatidylation of , provide mild action suitable for formulating creams and lotions. Biotechnological uses of phospholipases extend to biofuel production, where engineered (PLC) variants are applied to hydrolyze phospholipids in algal , aiding in the extraction and purification of triacylglycerols for feedstock and reducing issues during processing. Advances in the 2020s, including techniques like error-prone PCR, have produced thermostable PLC and PLD variants with improved half-lives at elevated temperatures, enhancing their viability for industrial-scale operations in modification and refinement. Additionally, PLA2 activity serves as a diagnostic in , with elevated group II PLA2 levels indicating intra-amniotic associated with preterm labor, allowing for early risk assessment. The global market for phospholipase enzymes was valued at approximately $300 million in 2024, with projections indicating growth to around $500 million by the early 2030s, primarily driven by demand in applications such as sustainable oil processing and biocatalysis.

References

  1. https://www.aocs.org/resource/phospholipases/
  2. https://www.sciencedirect.com/topics/neuroscience/phospholipase
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC8001435/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC3039968/
  5. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/phospholipase
  6. https://enzyme.expasy.org/EC/3.1.-.-
  7. https://www.aocs.org/resource/microbial-phospholipases/
  8. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/phospholipase
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC3196595/
  10. https://link.springer.com/article/10.1007/s12010-011-9190-6
  11. https://scholarworks.utrgv.edu/cgi/viewcontent.cgi?article=1257&context=bio_fac
  12. https://pubmed.ncbi.nlm.nih.gov/8336671/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC8658914/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC9862071/
  15. https://www.sciencedirect.com/topics/medicine-and-dentistry/phospholipase-a1
  16. https://www.sciencedirect.com/science/article/pii/S0022227520344096
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC5807221/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC2823292/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC2674709/
  20. https://lipidworld.biomedcentral.com/articles/10.1186/1476-511X-10-32
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC7809086/
  22. https://pubmed.ncbi.nlm.nih.gov/9428661/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC3638883/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4583093/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC3781385/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC6732780/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC8634861/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC7233427/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC2020506/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC133608/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC1779961/
  32. https://journals.iucr.org/d/issues/1999/01/00/gr0821/gr0821.pdf
  33. https://www.cell.com/structure/fulltext/S0969-2126(00)00150-7
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC9031518/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC2673038/
  36. https://www.sciencedirect.com/science/article/pii/S0021925819895431
  37. https://pubmed.ncbi.nlm.nih.gov/12779324/
  38. https://www.sciencedirect.com/science/article/pii/S1674205214607383
  39. https://www.sciencedirect.com/science/article/pii/S0944501317307541
  40. https://www.sciencedirect.com/science/article/pii/S0168827814004619
  41. https://www.sciencedirect.com/science/article/pii/S0888754305003794
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC3443688/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC11206408/
  44. https://etd.ohiolink.edu/acprod/odb_etd/ws/send_file/send?accession=osu1047485476&disposition=inline
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC2324005/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC8133832/
  47. https://www.jbc.org/article/S0021-9258%2818%2939278-0/pdf
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC3208028/
  49. https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-022-00549-5
  50. https://pubmed.ncbi.nlm.nih.gov/10893237/
  51. https://www.sciencedirect.com/science/article/pii/S0014579300013739
  52. https://www.jbc.org/article/S0021-9258%2819%2939374-3/pdf
  53. https://www.jbc.org/article/S0021-9258%2818%2939423-7/pdf
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC8193641/
  55. https://journals.physiology.org/doi/full/10.1152/physrev.2000.80.4.1291
  56. https://pubmed.ncbi.nlm.nih.gov/12587975/
  57. https://portlandpress.com/biochemj/article/291/3/825/27960/Influence-of-arachidonic-acid-on-indices-of
  58. https://www.sciencedirect.com/science/article/pii/S0021915024011419
  59. https://www.sciencedirect.com/science/article/pii/S0022227520335252
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC3350552/
  61. https://www.sciencedirect.com/science/article/pii/S0167488905000054
  62. https://www.sciencedirect.com/science/article/pii/S0021925820575765
  63. https://www.sciencedirect.com/science/article/pii/S104453230190332X
  64. https://www.sciencedirect.com/science/article/pii/S000634950771490X
  65. https://www.sciencedirect.com/science/article/pii/S0022227520301875
  66. https://www.sciencedirect.com/science/article/pii/S0021925820770043
  67. https://www.sciencedirect.com/science/article/abs/pii/S0968000418302664
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC8797975/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC4460191/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC4156727/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC1450240/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC6200938/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC4180337/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC3022355/
  75. https://pubmed.ncbi.nlm.nih.gov/2992597/
  76. https://pubmed.ncbi.nlm.nih.gov/7380202/
  77. https://pubmed.ncbi.nlm.nih.gov/28739210/
  78. https://pubmed.ncbi.nlm.nih.gov/9237245/
  79. https://pubmed.ncbi.nlm.nih.gov/1792553/
  80. https://pubmed.ncbi.nlm.nih.gov/25748412/
  81. https://pubmed.ncbi.nlm.nih.gov/18853146/
  82. https://pubmed.ncbi.nlm.nih.gov/23307660/
  83. https://pubmed.ncbi.nlm.nih.gov/27998778/
  84. https://pubmed.ncbi.nlm.nih.gov/28007986/
  85. https://pubmed.ncbi.nlm.nih.gov/19818633/
  86. https://pubmed.ncbi.nlm.nih.gov/16516698/
  87. https://pubmed.ncbi.nlm.nih.gov/15087463/
  88. https://pubmed.ncbi.nlm.nih.gov/9629537/
  89. https://www.tandfonline.com/doi/full/10.4161/psb.3.8.6186
  90. https://pubmed.ncbi.nlm.nih.gov/29309666/
  91. https://www.researchgate.net/publication/221760706_The_Patatin-Containing_Phospholipase_A_pPLAIIa_Modulates_Oxylipin_Formation_and_Water_Loss_in_Arabidopsis_thaliana
  92. https://www.scielo.br/j/bjpp/a/x3DDtcKxbJHg9kbf44pJzYH/?lang=en
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC150170/
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC173601/
  95. https://pubmed.ncbi.nlm.nih.gov/10085017/
  96. https://pubmed.ncbi.nlm.nih.gov/14528019/
  97. https://www.yeastgenome.org/locus/S000001739
  98. https://www.sciencedirect.com/science/article/abs/pii/S1388198121002298
  99. https://www.science.org/doi/10.1126/sciadv.adf5122
  100. https://pubmed.ncbi.nlm.nih.gov/8165440/
  101. https://pubmed.ncbi.nlm.nih.gov/1757123/
  102. https://pubmed.ncbi.nlm.nih.gov/11160764/
  103. https://pubmed.ncbi.nlm.nih.gov/31362705/
  104. https://pubmed.ncbi.nlm.nih.gov/33945837/
  105. https://pubmed.ncbi.nlm.nih.gov/33863362/
  106. https://pubmed.ncbi.nlm.nih.gov/17033970/
  107. https://pubmed.ncbi.nlm.nih.gov/24115030/
  108. https://pubmed.ncbi.nlm.nih.gov/9250614/
  109. https://pubmed.ncbi.nlm.nih.gov/18202189/
  110. https://pubmed.ncbi.nlm.nih.gov/39442939/
  111. https://gh.bmj.com/content/9/10/e015985
  112. https://pubmed.ncbi.nlm.nih.gov/6870935/
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC2938802/
  114. https://www.selleckchem.com/products/u73122.html
  115. https://pubmed.ncbi.nlm.nih.gov/1316230/
  116. https://ashpublications.org/blood/article/94/10/3583/125411/Liposomal-ET-18-OCH3-Induces-Cytochrome-c-Mediated
  117. https://aacrjournals.org/cancerres/article/85/8_Supplement_1/4346/759715
  118. https://www.researchgate.net/publication/23771224_Design_of_isoform-selective_phospholipase_D_inhibitors_that_modulate_cancer_cell_invasiveness
  119. https://www.medchemexpress.com/phospholipase-d.html
  120. https://www.sciencedirect.com/science/article/abs/pii/S0014299915300029
  121. https://www.ahajournals.org/doi/10.1161/atvbaha.115.305234
  122. https://pubs.acs.org/doi/10.1021/acsmedchemlett.6b00188
  123. https://pmc.ncbi.nlm.nih.gov/articles/PMC5968471/
  124. https://www.sciencedirect.com/science/article/pii/S2095311916614375
  125. https://pubmed.ncbi.nlm.nih.gov/24247616/
  126. https://clinicaltrials.gov/study/NCT05717062
  127. https://www.atsjournals.org/doi/abs/10.1164/ajrccm.2025.211.Abstracts.A6566
  128. https://www.nature.com/articles/s41413-025-00470-9
  129. https://medicalxpress.com/news/2025-11-enzyme-path-degenerative-joint-diseases.html
  130. https://www.nature.com/articles/nrd.2016.252
  131. https://onlinelibrary.wiley.com/doi/full/10.1111/cbdd.14466
  132. https://www.rxlist.com/how_do_phospholipase_a2_inhibitors_work/drug-class.htm
  133. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964%2825%2900044-1/fulltext
  134. https://pubmed.ncbi.nlm.nih.gov/8907240/
  135. https://pubmed.ncbi.nlm.nih.gov/9551934/
  136. https://pubmed.ncbi.nlm.nih.gov/21511545/
  137. https://pubmed.ncbi.nlm.nih.gov/2274785/
  138. https://pubmed.ncbi.nlm.nih.gov/39314324/
  139. https://pubmed.ncbi.nlm.nih.gov/9403693/
  140. https://pubmed.ncbi.nlm.nih.gov/34509476/
  141. https://www.nature.com/articles/s41598-019-40931-w
  142. https://pubmed.ncbi.nlm.nih.gov/37649605/
  143. https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01568
  144. https://www.aocs.org/resource/enzymatic-degumming/
  145. https://pubs.acs.org/doi/10.1021/acs.bioconjchem.6b00736
  146. https://www.mdpi.com/2073-4344/10/9/997
  147. https://biodieseleducation.org/Literature/TechNotes/TN23_Phosholipid_In_Biodiesel_Production.pdf
  148. https://pubmed.ncbi.nlm.nih.gov/32858108/
  149. https://pubmed.ncbi.nlm.nih.gov/11120524/
  150. https://www.futuremarketinsights.com/reports/phospholipase-enzyme-market
Add your contribution
Related Hubs
User Avatar
No comments yet.